ERBB2 and breast carcinoma: In particular, ganetespib offers a promising chemotherapeutic strategy for refractory ErbB2+ breast cancers, even in the presence of mutations in the extracellular and tyrosine kinase domains of ErbB2, which are associated with primary resistance to ErbB2-targeting therapeutics.